Vaxart (NASDAQ:VXRT) Shares Cross Below Two Hundred Day Moving Average of $0.88

Vaxart, Inc. (NASDAQ:VXRT)’s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.88 and traded as low as $0.63. Vaxart shares last traded at $0.66, with a volume of 1,919,722 shares traded.

Analysts Set New Price Targets

Separately, B. Riley raised Vaxart from a “neutral” rating to a “buy” rating and set a $2.00 price target for the company in a report on Wednesday, January 31st.

Vaxart Price Performance

The stock has a fifty day moving average price of $1.11 and a 200 day moving average price of $0.88.

Vaxart (NASDAQ:VXRT) last issued its quarterly earnings data on Thursday, March 14th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03. Vaxart had a negative return on equity of 108.45% and a negative net margin of 1,117.56%. The company had revenue of $3.25 million for the quarter, compared to the consensus estimate of $0.45 million. On average, research analysts anticipate that Vaxart, Inc. will post -0.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Vaxart

A number of institutional investors and hedge funds have recently made changes to their positions in the business. PFG Investments LLC purchased a new stake in shares of Vaxart in the first quarter worth $38,000. Kingswood Wealth Advisors LLC purchased a new stake in Vaxart during the first quarter valued at about $32,000. Beacon Capital Management LLC raised its position in Vaxart by 369.9% during the fourth quarter. Beacon Capital Management LLC now owns 50,814 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 40,000 shares in the last quarter. Finally, AE Wealth Management LLC raised its position in Vaxart by 180.7% during the third quarter. AE Wealth Management LLC now owns 62,113 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 39,987 shares in the last quarter. Hedge funds and other institutional investors own 18.05% of the company’s stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical dysplasia.